vs
Side-by-side financial comparison of MMTec, Inc. (MTC) and Scinai Immunotherapeutics Ltd. (SCNI). Click either name above to swap in a different company.
MMTec, Inc. is the larger business by last-quarter revenue ($807.5K vs $773.0K, roughly 1.0× Scinai Immunotherapeutics Ltd.).
MMTec, Inc. is a global fintech enterprise that develops and delivers integrated trading technology solutions, including high-performance trading platforms, real-time market data services, and risk management systems. Its core clients cover brokerage firms, asset management institutions, and professional traders across North America and the Asia-Pacific region, helping financial market participants boost trading efficiency and operational security.
MTC vs SCNI — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $807.5K | $773.0K |
| Net Profit | $-46.4M | — |
| Gross Margin | 83.5% | — |
| Operating Margin | -189.7% | — |
| Net Margin | -5749.7% | — |
| Revenue YoY | — | 172.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-1.84 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $807.5K | $773.0K | ||
| Q2 24 | — | $284.0K |
| Q2 25 | $-46.4M | — | ||
| Q2 24 | — | — |
| Q2 25 | 83.5% | — | ||
| Q2 24 | — | — |
| Q2 25 | -189.7% | — | ||
| Q2 24 | — | — |
| Q2 25 | -5749.7% | — | ||
| Q2 24 | — | — |
| Q2 25 | $-1.84 | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.2M | $989.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-19.8M | $7.9M |
| Total Assets | $20.3M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $10.2M | $989.0K | ||
| Q2 24 | — | $3.1M |
| Q2 25 | $-19.8M | $7.9M | ||
| Q2 24 | — | $-7.3M |
| Q2 25 | $20.3M | $11.8M | ||
| Q2 24 | — | $14.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-1.7M | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
